The association of FOXO3A gene polymorphisms with serum FOXO3A levels and oxidative stress markers in vitiligo patients

Gene

Volumn 536, Issue 1, 2014, Pages 129-134

  Ozel Turkcu, Ummuhani ^a   Solak Tekin, Nilgun ^b   Gokdogan Edgunlu, Tuba ^a   Karakas Celik, Sevim ^b   Oner, Setenay ^c  

^a MUGLA SITKI KOCMAN UNIVERSITY   (Turkey)

^b ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^c ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Advanced protein products; FOXO3A; Gene polymorphism; Oxidative stress; Vitiligo

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; CATALASE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR FKHRL1;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; VITILIGO; YOUNG ADULT;

EID: 84891833906     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.11.055     Document Type: Article

References (50)

1. Alagozlu H., Gorgul A., Bilgihan A., Tuncer C., Unal S. Increased plasma levels of advanced oxidation protein products (AOPP) as a marker for oxidative stress in patients with active ulcerative colitis. Clin Res Hepatol Gastroenterol 2013, 37(1):80-85.
2. Anderson M.J., Viars C.S., Czekay S., Cavenee W.K., Arden K.C. Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics 1998, 47:187-199.
3. Anselmi C.V., et al. Association of the FOXO3A locus with extreme longevity in a southern Italian centenarian study. Rejuvenation Res 2009, 12(2):95-104.
4. Banasik K., et al. The FOXO3A rs2802292 G-allele associates with improved peripheral and hepatic insulin sensitivity and increased skeletal muscle-FOXO3A mRNA expression in twins. J Clin Endocrinol Metab 2011, 96(1):E119-E124.
5. Beazley W.D., Gaze D., Panske A., Panzig E., Schallreuter K.U. Serum selenium levels and blood glutathione peroxidase activities in vitiligo. Br J Dermatol 1999, 141:301-303.
6. Brunet A., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96(6):857-868.
7. Brunet A., et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.
8. Casp C.B., She J.X., McCormack W.T. Genetic association of the catalase gene (CAT) with vitiligo susceptibility. Pigment Cell Res 2002, 15:62-66.
9. Chiribau C.B., Cheng L., Cucoranu I.C., Yu Y.S., Clempus R.E., Sorescu D. FOXO3A regulates peroxiredoxin III expression in human cardiac fibroblasts. J Biol Chem 2008, 283(13):8211-8217.
10. Courtney B.C., Jin-Xiong S., Wayne T.M. Genetic association of the catalase gene (CAT) with vitiligo susceptibility. Pigment Cell Res 2002, 15(1):62-66.
11. Essers M.A., et al. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J 2004, 23(24):4802-4812.
12. Flachsbart F., et al. Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc Natl Acad Sci U S A 2009, 106:2700-2705.
13. Furukawa-Hibi Y., Kobayashi Y., Chen C., Motoyama N. FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid Redox Signal 2005, 7(5-6):752-760.
14. Halder R.M., Chappell J.L. Vitiligo update. Semin Cutan Med Surg 2009, 28(2):86-92.
15. Hanasand M., Omdal R., Norheim K.B., Gøransson L.G., Brede C., Jonsson G. Improved detection of advanced oxidation protein products in plasma. Clin Chim Acta 2012, 413(9-10):901-916.
16. Hazneci E., et al. A comparative study of superoxide dismutase, catalase, and glutathione peroxidase activities and nitrate levels in vitiligo patients. Int J Dermatol 2005, 44(8):636-640.
17. Huang C.L., Nordlund J.J., Boissy R. Vitiligo: a manifestation of apoptosis?. Am J Clin Dermatol 2002, 5:301-308.
18. Imran M., et al. Interleukin-4 genetic variants correlate with its transcript and protein levels in patients with vitiligo. Br J Dermatol 2012, 167(2):314-323.
19. Jain A., Mal J., Mehndiratta V., Chander R., Patra S.K. Study of oxidative stress in vitiligo. Indian J Clin Biochem 2011, 26(1):78-81.
20. Jimbow K., Chen H., Park S., Thomas P.D. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of trosinase-related protein in vitiligo. Br J Dermatol 2001, 144:55-65.
21. Karaca N., Ozturk G., Gerceker B.T., Turkmen M., Berdeli A. TLR2 and TLR4 gene polymorphisms in Turkish vitiligo patients. J Eur Acad Dermatol Venereol 2013, 27(1):e85-e90.
22. Kim J.R., et al. Polymorphisms in FOXO gene family and association analysis with BMI. Obesity (Silver Spring) 2006, 14(2):188-193.
23. Klagge A., Weidinger C., Krause K., Jessnitzer B., Gutknecht M., Fuhrer D. The role of FOXO3 in DNA damage response in thyrocytes. Endocr Relat Cancer 2011, 18(5):555-564.
24. Koca R., Armutcu F., Altinyazar H.C., Gürel A. Oxidant-antioxidant enzymes and lipid peroxidation in generalized vitiligo. Clin Exp Dermatol 2004, 29:406-409.
25. Kops G.J., et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002, 419(6904):316-321.
26. Liu L., et al. Promoter variant in the catalase gene is associated with vitiligo in Chinese people. J Invest Dermatol 2010, 130(11):2647-2653.
27. Lu Q., et al. The Akt-FoxO3a-manganese superoxide dismutase pathway is involved in the regulation of oxidative stress in diabetic nephropathy. Exp Physiol 2013, 98(4):934-945.
28. Magno L.A., et al. Genetic variations in FOXO3A are associated with Bipolar Disorder without confering vulnerability for suicidal behavior. J Affect Disord 2001, 133(3):633-637.
29. Maiese K., Chong Z.Z., Hou J., Shang Y.C. The "O" class: crafting clinical care with FoxO transcription factors. Adv Exp Med Biol 2009, 665:242-260.
30. Maresca V., et al. Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo. J Invest Dermatol 1997, 109(3):303-310.
31. Nemoto S., Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 2002, 295(5564):2450-2452.
32. Nogueira V., et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008, 14:458-470.
33. Olmos Y., et al. Mutual dependence of Foxo3a and PGC-1alpha in the induction of oxidative stress genes. J Biol Chem 2009, 284(21):14476-14484.
34. Ortonne J.P. Vitiligo and other disorders of hypopigmentation. Dermatology 2008, 913. Mosby Elsevier, Philadelphia. 2nd ed. J.L. Bolognia, J.L. Jorizzo, R.P. Rapini (Eds.).
35. Passeron T., Ortonne J.P. Physiopathology and genetics of vitiligo. J Autoimmun 2005, 25:63-68.
36. Plas D.R., Thompson C.B. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem 2003, 278(14):12361-12366.
37. Ponugoti B., Dong G., Graves D.T. Role of forkhead transcription factors in diabetes-induced oxidative stress. Exp Diabetes Res 2012, 2012:939751-939757.
38. Schallreuter K.U., Wood J.M., Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991, 97:1081-1085.
39. Schallreuter K.U., et al. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochim Biophys Acta 1994, 1226(2):181-192.
40. 2) accumulation in the epidermis of patientswith vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investing Dermatol Symp Proc 1999, 4(1):91-96.
41. Shajil E.M., Chatterjee S., Agrawal D., Bagchi T., Begum R. Vitiligo: pathomechanisms and genetic polymorphism of susceptible genes. Indian J Exp Biol 2006, 44(7):526-539.
42. Shukla S., Shukla M., Maclennan G.T., Fu P., Gupta S. Deregulation of FOXO3A during prostate cancer progression. Int J Oncol 2009, 34(6):1613-1620.
43. Sies H. Oxidative stress: from basic research to clinical application. Am J Med 1991, 91:31S-38S.
44. Sravani P.V., et al. Determination of oxidative stress in vitiligo by measuring superoxide dismutase and catalase levels in vitiliginous and non-vitiliginous skin. Indian J Dermatol Venereol Leprol 2009, 75(3):268-271.
45. Sun Y., Oberley L.W., Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988, 34(3):497-500.
46. Willcox B.J., et al. FOXO3A genotype is strongly associated with human longevity. Proc Natl Acad Sci U S A 2008, 105:13987-13992.
47. Witko-Sarsat V., et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996, 49(5):1304-1313.
48. Yalcin S., et al. Foxo3 is essential for the regulation of ataxia telangiectasia mutated and oxidative stress-mediated homeostasis of hematopoietic stem cells. J Biol Chem 2008, 283(37):25692-25705.
49. Yang J.Y., et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 2008, 10:138-148.
50. Yildirim M., Baysal V., Inaloz H.S., Kesici D., Delibas N. The role of oxidants and antioxidants in generalized vitiligo. J Dermatol 2003, 30(2):104-108.